EGFR Atypical Lung Cancer Signal Advances Toward Randomized Test
ORIC reported a high response rate for enozertinib in a small first-line EGFR-atypical non-small-cell lung cancer Phase 1b cohort, including intracranial activity, and outlined a 2027 randomized Phase 3. The main uncertainty is durability…
